Skip to content
Opening soonHORIZON-MISS-2027-02-CANCER-02HaDEAOne-off

Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers

Clinical research by Comprehensive Cancer Infrastructures.

Horizon Europe innovation action (€20 million, lump sum) under the EU Mission on Cancer for clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers.

Opening soon
84
days until opening
Opens on 10 February 2027
HORIZON-MISS-2027-02-CANCER-02
View all deadlines
Beta

This grant database is in beta

Until the official launch on 1 January 2027 we are making the final improvements. Our editors check every scheme, but details may still be incomplete or out of date. Check the official publication before you apply.

In brief

What is Clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers?

Who
A consortium of at least three independent organisations from three different EU Member States or Associated Countries, at least one of which is from a Member State. Companies of any size, research organisations, public authorities, foundations and associations can take part.
General Annex B (Entities eligible to participate; Entities eligible for funding; Consortium composition)
What for
An innovation action in which Comprehensive Cancer Infrastructures in Europe jointly carry out clinical research on the diagnosis and treatment of lung, colorectal, breast or prostate cancer, for better health outcomes for patients with these common cancers.
Topic HORIZON-MISS-2027-02-CANCER-02 (Expected Outcome; Scope)
What you get
A lump sum grant of up to 70% of eligible costs; the Commission considers an EU contribution of €7 million to €10 million per project appropriate. The indicative budget for the topic is €20 million, expected to fund 3 projects.
Topic HORIZON-MISS-2027-02-CANCER-02 (Expected EU contribution per project; Indicative budget; Legal and financial set-up); General Annex G, Funding rates
What you need to do
Submit a proposal in a single stage via the Funding & Tenders Portal from 10 February 2027 until 16 September 2027 (17:00 Brussels time) at the latest, with application form Part A and Part B, a detailed budget table for the lump sum and an annex on the clinical study/studies. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.
Call HORIZON-MISS-2027-02 overview (Opening; Deadline); General Annexes E and F

Built from the details on this page, with nothing added by us.

Purpose & impact

Why does this scheme exist?

Better health outcomes for patients with common cancers.

01
Better diagnosis and treatment for patients
Patients with lung, colorectal, breast or prostate cancer benefit from evidence-based, affordable and accessible clinical research programmes run by Comprehensive Cancer Infrastructures.
02
Opportunities for research and innovation
Researchers, clinicians, patient representatives, funders, insurers, SMEs and innovators co-create, support, scale up or commercialise the results of these clinical programmes.
03
Evidence for health policy
Healthcare providers, healthcare payers and policymakers in European regions, Member States and Associated Countries have the evidence to test, scale up or introduce appropriate clinical research programmes.
Description

About the scheme

Compiled from passages of the scheme's official publication, with nothing added by us.

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: - Patients afflicted by lung, bowel, breast or prostate cancer, will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures. - Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. - National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

Am I eligible?

Conditions

Quoted verbatim from the scheme, with the article that sets each condition.

01
To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions: … – countries associated to Horizon Europe
02
Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.
03
Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.
All sizes
Micro< 10 FTE
Small< 50 FTE
Medium< 250 FTE
Large≥ 250 FTE
Themes
Onderzoek, ontwikkeling en innovatieGezondheid, zorg en welzijn
Project phase
DevelopmentDemonstration
Funding

What do you get?

70% of your eligible project costs.

Note on the maximum
No binding maximum; the Commission considers an EU contribution of €7-10 million per project appropriate (other amounts not excluded).
€20m · Indicative topic budget, 3 projects expected to be funded.
Budget status
Not published by the source
The sources do not say how much budget is left (checked 18 November 2026).
No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared to two different EU actions (General Annex G).
Type
Direct grant (non-repayable)
Calendar

Deadlines & cycles

10
FEB
HORIZON-MISS-2027-02-CANCER-02 opens 10 February 2027
Call HORIZON-MISS-2027-02, overview of this call
Cycle: Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F). General Annex F, Indicative timetable for evaluation and for signature of the grant agreement
Application

How do you apply?

Pre-registration
Required, before the full application
Required attachments
  • Application form Part A: administrative data of the participants and summarised budget (to be completed online)
  • Application form Part B: technical description of the project (PDF, maximum 45 pages)
  • Detailed budget table (HE LS template) for the lump sum contribution
  • Annex with information on the clinical study/studies (HE template)
Procedure
Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).
Eligible costs

What can the money be spent on?

Personnel costs
Materials
Not eligible
Subcontracting
Equipment
Land
Not eligible
Buildings
Not eligible
Overheads
Travel costs
Other costs
Lump sum: fixed contribution per work package, no cost reporting (lump sum decision of 7 July 2021). Funding rate 70%; non-profit legal entities 100%.
Downloads

Files & forms

Changes

What has changed?

10 November 2026scheme · version 5

Subtitle
Subtitle: ChangedShow
Before

Klinisch onderzoek door uitgebreide kankerinfrastructuren.

Now

Clinical research by Comprehensive Cancer Infrastructures.

Description
Description: ChangedShow
Before

Projecten voeren klinisch onderzoek uit via netwerken van Comprehensive Cancer Infrastructures om diagnose en behandeling van patiënten met veelvoorkomende kankers te verbeteren. Hogere drempels bij de beoordeling: 4 per criterium en 12 in totaal.

Now

Projects carry out clinical research through networks of Comprehensive Cancer Infrastructures to improve the diagnosis and treatment of patients with common cancers. Higher evaluation thresholds apply: 4 per criterion and 12 in total.

Short description
Short description: ChangedShow
Before

Horizon Europe innovatieactie (€ 20 mln, lump sum) binnen de EU-missie Kanker voor klinisch onderzoek door Comprehensive Cancer Infrastructures ten behoeve van patiënten met veelvoorkomende kankers.

Now

Horizon Europe innovation action (€20 million, lump sum) under the EU Mission on Cancer for clinical research by Comprehensive Cancer Infrastructures for the benefit of patients with common cancers.

Cycle
Cycle: ChangedShow
Before

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Now

Evaluation results around 5 months after the deadline; signature of the grant agreement around 8 months after the deadline (General Annex F).

Note on the total budget
Note on the total budget: ChangedShow
Before

Indicatief topicbudget, naar verwachting 3 projecten.

Now

Indicative topic budget, 3 projects expected to be funded.

Note on the maximum
Note on the maximum: ChangedShow
Before

Geen bindend maximum; de Commissie acht € 7 tot 10 mln EU-bijdrage per project passend (andere bedragen niet uitgesloten).

Now

No binding maximum; the Commission considers an EU contribution of €7-10 million per project appropriate (other amounts not excluded).

Cumulation
Cumulation: ChangedShow
Before

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Now

No double funding: an action may receive only one grant from the EU budget (except EU Synergy grants) and the same costs may never be declared to two different EU actions (General Annex G).

Search engine title
Klinisch kankeronderzoek via kankerinfrastructuren becomes Clinical cancer research via cancer infrastructures
Search engine description
Search engine description: ChangedShow
Before

Horizon Europe innovatieactie van € 20 mln voor klinisch onderzoek door Comprehensive Cancer Infrastructures binnen de EU-missie Kanker.

Now

Horizon Europe innovation action of €20 million for clinical research by Comprehensive Cancer Infrastructures under the EU Mission on Cancer.

Keywords
EU-missie Cancer, Horizon Europe, HORIZON-MISS-2027-02-CANCER-02, kankerinfrastructuren, klinisch kankeronderzoek, veelvoorkomende kankers becomes cancer infrastructures, clinical cancer research, common cancers, EU Mission Cancer, Horizon Europe, HORIZON-MISS-2027-02-CANCER-02
Language
Dutch (Netherlands) becomes British English
Required attachments
Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 45 pagina's); Gedetailleerde begrotingstabel (HE LS-sjabloon) voor de lump-sumbijdrage; Bijlage met informatie over de klinische studie(s) (HE-sjabloon) becomes Application form Part A: administrative data of the participants and summarised budget (to be completed online); Application form Part B: technical description of the project (PDF, maximum 45 pages); Detailed budget table (HE LS template) for the lump sum contribution; Annex with information on the clinical study/studies (HE template)
Procedure
Procedure: ChangedShow
Before

Aanvragen via het Funding & Tenders Portal met een EU Login en een PIC-nummer; single-stage; deadline 17:00 uur Brusselse tijd; beheerd door European Health and Digital Executive Agency (HaDEA).

Now

Apply via the Funding & Tenders Portal with an EU Login and a PIC number; single-stage; deadline 17:00 Brussels time; managed by the European Health and Digital Executive Agency (HaDEA).

Notes per cost type
Notes per cost type: ChangedShow
Before

Other costs: Lump sum: vaste bijdrage per werkpakket, geen kostenverantwoording (lumpsumbesluit van 7 juli 2021). Financieringspercentage 70%; non-profit rechtspersonen 100%.

Now

Other costs: Lump sum: fixed contribution per work package, no cost reporting (lump sum decision of 7 July 2021). Funding rate 70%; non-profit legal entities 100%.

Why this scheme
Why this scheme: ChangedShow
Before

Betere zorguitkomsten voor patiënten met veelvoorkomende kankers.

Now

Better health outcomes for patients with common cancers.

In brief
In brief: ChangedShow
Before

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat. Bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen.

What for: Een innovatieactie waarin uitgebreide kankerinfrastructuren in Europa samen klinisch onderzoek doen naar diagnose en behandeling van long-, darm-, borst- of prostaatkanker, voor betere zorguitkomsten voor patiënten met deze veelvoorkomende kankers.

What you get: Een lump-sumsubsidie tot 70% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot € 10 miljoen per project passend. Het indicatieve budget voor het topic is € 20 miljoen, naar verwachting voor 3 projecten.

What you need to do: Dien van 10 februari 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en B, een gedetailleerde begrotingstabel voor de lump sum en een bijlage over de klinische studie(s). Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

Now

Who: A consortium of at least three independent organisations from three different EU Member States or Associated Countries, at least one of which is from a Member State. Companies of any size, research organisations, public authorities, foundations and associations can take part.

What for: An innovation action in which Comprehensive Cancer Infrastructures in Europe jointly carry out clinical research on the diagnosis and treatment of lung, colorectal, breast or prostate cancer, for better health outcomes for patients with these common cancers.

What you get: A lump sum grant of up to 70% of eligible costs; the Commission considers an EU contribution of €7 million to €10 million per project appropriate. The indicative budget for the topic is €20 million, expected to fund 3 projects.

What you need to do: Submit a proposal in a single stage via the Funding & Tenders Portal from 10 February 2027 until 16 September 2027 (17:00 Brussels time) at the latest, with application form Part A and Part B, a detailed budget table for the lump sum and an annex on the clinical study/studies. Independent experts evaluate and rank the proposals; results are expected around 5 months after the deadline.

Goals
Goals: 3 removed, 3 newShow
Removed

Betere diagnose en behandeling voor patiënten Patiënten met long-, darm-, borst- of prostaatkanker profiteren van evidence-based, betaalbare en toegankelijke klinische onderzoeksprogramma's van uitgebreide kankerinfrastructuren.

Kansen voor onderzoek en innovatie Onderzoekers, artsen, patiëntvertegenwoordigers, fondsen, verzekeraars, mkb en innovatoren co-creëren, ondersteunen, schalen op of commercialiseren de uitkomsten van deze klinische programma's.

Bewijs voor zorgbeleid Zorgaanbieders, zorgbetalers en beleidsmakers in Europese regio's, lidstaten en geassocieerde landen hebben het bewijs om passende klinische onderzoeksprogramma's te testen, op te schalen of in te voeren.

New

Better diagnosis and treatment for patients Patients with lung, colorectal, breast or prostate cancer benefit from evidence-based, affordable and accessible clinical research programmes run by Comprehensive Cancer Infrastructures.

Opportunities for research and innovation Researchers, clinicians, patient representatives, funders, insurers, SMEs and innovators co-create, support, scale up or commercialise the results of these clinical programmes.

Evidence for health policy Healthcare providers, healthcare payers and policymakers in European regions, Member States and Associated Countries have the evidence to test, scale up or introduce appropriate clinical research programmes.

Show 4 earlier versions

20 October 2026scheme · version 4

Conditions
Conditions: 2 removed, 3 newShow
Removed

Consortium van minstens drie partners Minstens drie onafhankelijke juridische entiteiten uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat (General Annex B).

Hogere beoordelingsdrempels De drempel is 4 voor Excellence, Impact en Implementation, met een cumulatieve drempel van 12 (afwijking van General Annex D).

New

To be eligible for funding, applicants must be established in one of the following countries: – the Member States of the European Union, including their outermost regions: … – countries associated to Horizon Europe

Unless otherwise provided for in the specific call/topic conditions, only legal entities forming a consortium are eligible to participate in actions provided that the consortium includes, as beneficiaries, three legal entities independent from each other and each established in a different country as follows: – at least one independent legal entity established in a Member State; and – at least two other independent legal entities, each established in different Member States or Associated Countries.

Applications will only be considered eligible if their content corresponds, wholly or in part, to the topic description for which it is submitted.

In brief
In brief: AddedShow
Now

Who: Een consortium van ten minste drie onafhankelijke organisaties uit drie verschillende EU-lidstaten of geassocieerde landen, waarvan minstens één uit een lidstaat. Bedrijven van elke omvang, onderzoeksinstellingen, overheden, stichtingen en verenigingen kunnen deelnemen.

What for: Een innovatieactie waarin uitgebreide kankerinfrastructuren in Europa samen klinisch onderzoek doen naar diagnose en behandeling van long-, darm-, borst- of prostaatkanker, voor betere zorguitkomsten voor patiënten met deze veelvoorkomende kankers.

What you get: Een lump-sumsubsidie tot 70% van de subsidiabele kosten; de Commissie acht een EU-bijdrage van € 7 tot € 10 miljoen per project passend. Het indicatieve budget voor het topic is € 20 miljoen, naar verwachting voor 3 projecten.

What you need to do: Dien van 10 februari 2027 tot uiterlijk 16 september 2027 (17:00 uur Brusselse tijd) in één ronde een voorstel in via het Funding & Tenders Portal, met aanvraagformulier deel A en B, een gedetailleerde begrotingstabel voor de lump sum en een bijlage over de klinische studie(s). Onafhankelijke experts beoordelen en rangschikken de voorstellen; de uitslag volgt naar verwachting circa 5 maanden na de deadline.

18 October 2026scheme · version 3

About the scheme
About the scheme: AddedShow
Now

Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes: - Patients afflicted by lung, bowel, breast or prostate cancer, will benefit from the outcomes of evidence-based, tailored, innovative, affordable and accessible diagnosis- and treatment-centred clinical research programmes by comprehensive cancer infrastructures. - Researchers, physicians, patient representatives, civil society, charities, foundations, insurance companies, SMEs and innovators will seize opportunities to respectively co-create, support, upscale or commercialise outcomes of evidence-based, tailored, affordable and accessible clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer. - National and regional healthcare providers, healthcare payers, policymakers and authorities in European regions, EU Member States and Associated Countries have the evidence to engage in piloting, upscaling or implementing appropriate clinical research programmes for the diagnosis and treatment of patients afflicted by lung, bowel, breast or prostate cancer.

16 October 2026scheme · version 2

Cycle
Cycle: AddedShow
Now

Uitslag van de evaluatie rond 5 maanden na de deadline; ondertekening van de subsidieovereenkomst rond 8 maanden na de deadline (General Annex F).

Cumulation
Cumulation: AddedShow
Now

Geen dubbele financiering: een actie kan maar één subsidie uit de EU-begroting krijgen (behalve EU Synergy grants) en dezelfde kosten mogen nooit bij twee verschillende EU-acties worden gedeclareerd (General Annex G).

Keywords
Added: EU-missie Cancer, Horizon Europe, HORIZON-MISS-2027-02-CANCER-02, kankerinfrastructuren, klinisch kankeronderzoek, veelvoorkomende kankers
Required attachments
Added: Aanvraagformulier deel A: administratieve gegevens van de deelnemers en samengevatte begroting (online in te vullen); Aanvraagformulier deel B: technische beschrijving van het project (pdf, maximaal 45 pagina's); Gedetailleerde begrotingstabel (HE LS-sjabloon) voor de lump-sumbijdrage; Bijlage met informatie over de klinische studie(s) (HE-sjabloon)
Goals
Goals: 3 newShow
New

Betere diagnose en behandeling voor patiënten Patiënten met long-, darm-, borst- of prostaatkanker profiteren van evidence-based, betaalbare en toegankelijke klinische onderzoeksprogramma's van uitgebreide kankerinfrastructuren.

Kansen voor onderzoek en innovatie Onderzoekers, artsen, patiëntvertegenwoordigers, fondsen, verzekeraars, mkb en innovatoren co-creëren, ondersteunen, schalen op of commercialiseren de uitkomsten van deze klinische programma's.

Bewijs voor zorgbeleid Zorgaanbieders, zorgbetalers en beleidsmakers in Europese regio's, lidstaten en geassocieerde landen hebben het bewijs om passende klinische onderzoeksprogramma's te testen, op te schalen of in te voeren.

7 October 2026scheme · version 1 · first publication

Source

Contact & source

Funding body
European Health and Digital Executive Agency
Last verified
17 November 2026 by the Twin editors
Start your application

Start your HORIZON-MISS-2027-02-CANCER-02 application
in Twin.

Twin helps you write your application, based on the scheme and your own project documents. You stay in control of every text.